1Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007; 370(9590): 851-858.
2Si T, Huang J, Yu X (translated edition). Essentials of psychopharmacology: basics and clinical appfication of neuroscience. 3rd Editied by Stephen M. Stahl. Beijing: Peking University Medical Press, 2011. (in Chinese).
3Chen J, Gao K, Kemp D E. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011; 24(1): 10-17.
4Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982; 4(3): 173- 193.
5Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am ./Psychiatry 1992; 149(6): 733-745.
6Jc N. The Use of Antipsychotc Drugs in the Treatment of Depression. New York: PMA Publishing Corp., 1987.
7Kennedy SH, Lam RW, Cohen NL, Ravindran AV, CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46 (Suppl 1): 38S-58S.
8Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Herr M, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19(7): 520-532.
9Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S. Increase of ant-ipsychotic medication in depressive inpat-ients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmaco12012; 15(4): 449-457.
10Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical a ntipsychotics. J Manag Care Pharm 2012; 18(5 Suppl B): 51-$20.
